Form 8-K RAPT Therapeutics, Inc. For: Nov 12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Leerink Partners Reiterates Market Perform Rating on Rapt Therapeutics (RAPT)
November 12, 2024 4:08 PM ESTLeerink Partners analyst Thomas Smith reiterated a Market Perform rating and $2.00 price target on Rapt Therapeutics (NASDAQ: RAPT).
The analyst comments "Bottom Line: RAPT reported 3Q24 financial results following the company's decision to terminate development of zelnecirnon (RPT193, oral CCR4 antagonist) based on recent FDA feedback suggesting there was no viable path forward for this program (see our note HERE).... More
Stifel Downgrades Rapt Therapeutics (RAPT) to Hold
November 12, 2024 4:04 PM ESTStifel analyst Alex Thompson downgraded Rapt Therapeutics (NASDAQ: RAPT) from Buy to Hold with a price target of $2.00 (from $7.00).
The analyst comments "We are downgrading RAPT to Hold following the recent Zelnecirnon program termination (LINK). RAPT discontinued the program following FDA feedback suggesting... More
